Table 3:
Estimated NNV with herpes zoster vaccines to prevent herpes zoster–related events, by age at vaccination
| Herpes zoster–related event, by age at vaccination* | Type of vaccine; median NNV (90% UI) | |
|---|---|---|
| Live attenuated vaccine | Recombinant subunit vaccine | |
| 50 yr | ||
| Herpes zoster | 15 (6–28) | 7 (5–26) |
| Ophthalmic herpes zoster | 103 (34–230) | 49 (29–193) |
| Postherpetic neuralgia | 106 (26–341) | 36 (22–288) |
| Hospital admission | 638 (103–2419) | 171 (84–2061) |
| Death | 71 898 (13 407–2 610 325) | 19 473 (11 148–2 200 338) |
| 60 yr | ||
| Herpes zoster | 18 (9–28) | 8 (6–21) |
| Ophthalmic herpes zoster | 122 (56–229) | 54 (34–150) |
| Postherpetic neuralgia | 78 (31–150) | 33 (23–128) |
| Hospital admission | 463 (119–1136) | 149 (84–947) |
| Death | 39 072 (14 670–91 623) | 15 915 (10 625–8621) |
| 65 yr | ||
| Herpes zoster | 21 (13–31) | 8 (6–18) |
| Ophthalmic herpes zoster | 138 (76–285) | 57 (37–138) |
| Postherpetic neuralgia | 64 (33–93) | 31 (23–73) |
| Hospital admission | 335 (124–700) | 137 (82–613) |
| Death | 27 828 (14 354–41 590) | 13 672 (9865–32 620) |
| 70 yr | ||
| Herpes zoster | 28 (21–43) | 9 (7–19) |
| Ophthalmic herpes zoster | 196 (123–362) | 65 (43–139) |
| Postherpetic neuralgia | 73 (42–96) | 35 (27–73) |
| Hospital admission | 289 (133–494) | 130 (83–385) |
| Death | 32 120 (18 131–43 416) | 15 753 (11 630–32 797) |
| 75 yr | ||
| Herpes zoster | 42 (32–63) | 11 (9–19) |
| Ophthalmic herpes zoster | 295 (171–586) | 77 (48–161) |
| Postherpetic neuralgia | 78 (51–102) | 40 (31–71) |
| Hospital admission | 215 (126–378) | 116 (75–226) |
| Death | 34 638 (21 718–50 059) | 18 139 (13 206–32 667) |
| 80 yr | ||
| Herpes zoster | 75 (47–125) | 14 (11–22) |
| Ophthalmic herpes zoster | 523 (257–1136) | 96 (60–190) |
| Postherpetic neuralgia | 97 (68–126) | 50 (40–80) |
| Hospital admission | 269 (169–466) | 145 (95–267) |
| Death | 43 125 (29 410–61 470) | 22 811 (16 801–37 057) |
| 85 yr | ||
| Herpes zoster | 142 (67–380) | 18 (15–25) |
| Ophthalmic herpes zoster | 983 (377–3133) | 124 (79–237) |
| Postherpetic neuralgia | 124 (94–164) | 66 (52–94) |
| Hospital admission | 351 (229–604) | 188 (125–328) |
| Death | 55 957 (40 079–79 288) | 29 816 (22 096–44 152) |
Note: 90% UI = uncertainty interval (based on 5th and 95th percentiles of 30 000 simulation results), NNV = number needed to vaccinate.
*
Ages shown are individuals’ exact age.